Does the media favor RVMD or VRTX?

In the previous week, Revolution Medicines had 2 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 24 mentions for Revolution Medicines and 22 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 0.63 beat Revolution Medicines' score of 0.57 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 14 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vertex Pharmaceuticals 11 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to REGN or RVMD?

In the previous week, Revolution Medicines had 1 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 24 mentions for Revolution Medicines and 23 mentions for Regeneron Pharmaceuticals. Revolution Medicines' average media sentiment score of 0.57 beat Regeneron Pharmaceuticals' score of 0.56 indicating that Revolution Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 9 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Revolution Medicines 14 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RVMD or ARGX?

In the previous week, Revolution Medicines had 18 more articles in the media than argenex. MarketBeat recorded 24 mentions for Revolution Medicines and 6 mentions for argenex. Revolution Medicines' average media sentiment score of 0.57 beat argenex's score of 0.30 indicating that Revolution Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 14 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive argenex 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer MRNA or RVMD?

In the previous week, Moderna had 9 more articles in the media than Revolution Medicines. MarketBeat recorded 33 mentions for Moderna and 24 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 0.57 beat Moderna's score of 0.40 indicating that Revolution Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 11 Very Positive mention(s) 8 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Revolution Medicines 14 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RVMD or NTRA?

In the previous week, Revolution Medicines had 13 more articles in the media than Natera. MarketBeat recorded 24 mentions for Revolution Medicines and 11 mentions for Natera. Natera's average media sentiment score of 0.91 beat Revolution Medicines' score of 0.57 indicating that Natera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 14 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Natera 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Revolution Medicines (RVMD) Competitors

$190.95 -5.99 (-3.04%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$190.75 -0.20 (-0.10%)

As of 09/18/2026 07:56 PM Eastern

Compare

RVMD vs. VRTX, REGN, ARGX, MRNA, and NTRA

Should you buy Revolution Medicines stock or one of its competitors? Revolution Medicines's main competitors and comparable companies include Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), argenex (ARGX), Moderna (MRNA), and Natera (NTRA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Revolution Medicines compare to Vertex Pharmaceuticals?

Revolution Medicines (NASDAQ:RVMD) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.

Revolution Medicines presently has a consensus price target of $226.17, suggesting a potential upside of 18.44%. Vertex Pharmaceuticals has a consensus price target of $570.83, suggesting a potential upside of 12.29%. Given Revolution Medicines' higher probable upside, equities analysts plainly believe Revolution Medicines is more favorable than Vertex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.95
Vertex Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.96

In the previous week, Revolution Medicines had 2 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 24 mentions for Revolution Medicines and 22 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 0.63 beat Revolution Medicines' score of 0.57 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	14 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vertex Pharmaceuticals	11 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Positive

Vertex Pharmaceuticals has a net margin of 35.00% compared to Revolution Medicines' net margin of 0.00%. Vertex Pharmaceuticals' return on equity of 23.09% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-88.20%	-57.85%
Vertex Pharmaceuticals	35.00%	23.09%	16.72%

Revolution Medicines has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market. Comparatively, Vertex Pharmaceuticals has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market.

94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Vertex Pharmaceuticals has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	3,534.39	-$1.13B	-$8.82	N/A
Vertex Pharmaceuticals	$12.00B	10.75	$3.95B	$17.18	29.59

Summary

Vertex Pharmaceuticals beats Revolution Medicines on 10 of the 17 factors compared between the two stocks.

How does Revolution Medicines compare to Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Revolution Medicines (NASDAQ:RVMD) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

Regeneron Pharmaceuticals has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34B	5.63	$4.50B	$40.46	19.40
Revolution Medicines	$11.58M	3,534.39	-$1.13B	-$8.82	N/A

83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are held by company insiders. Comparatively, 7.6% of Revolution Medicines shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Revolution Medicines had 1 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 24 mentions for Revolution Medicines and 23 mentions for Regeneron Pharmaceuticals. Revolution Medicines' average media sentiment score of 0.57 beat Regeneron Pharmaceuticals' score of 0.56 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	9 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Revolution Medicines	14 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Regeneron Pharmaceuticals currently has a consensus price target of $802.18, suggesting a potential upside of 2.21%. Revolution Medicines has a consensus price target of $226.17, suggesting a potential upside of 18.44%. Given Revolution Medicines' stronger consensus rating and higher possible upside, analysts plainly believe Revolution Medicines is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.58
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.95

Regeneron Pharmaceuticals has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market.

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Revolution Medicines' net margin of 0.00%. Regeneron Pharmaceuticals' return on equity of 13.47% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%
Revolution Medicines	N/A	-88.20%	-57.85%

Summary

Revolution Medicines beats Regeneron Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Revolution Medicines compare to argenex?

Revolution Medicines (NASDAQ:RVMD) and argenex (NASDAQ:ARGX) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

argenex has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	3,534.39	-$1.13B	-$8.82	N/A
argenex	$4.25B	14.58	$1.29B	$26.04	38.03

In the previous week, Revolution Medicines had 18 more articles in the media than argenex. MarketBeat recorded 24 mentions for Revolution Medicines and 6 mentions for argenex. Revolution Medicines' average media sentiment score of 0.57 beat argenex's score of 0.30 indicating that Revolution Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	14 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
argenex	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

argenex has a net margin of 32.19% compared to Revolution Medicines' net margin of 0.00%. argenex's return on equity of 43.59% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-88.20%	-57.85%
argenex	32.19%	43.59%	36.66%

94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 60.3% of argenex shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by insiders. Comparatively, 2.4% of argenex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Revolution Medicines has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market. Comparatively, argenex has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market.

Revolution Medicines presently has a consensus target price of $226.17, suggesting a potential upside of 18.44%. argenex has a consensus target price of $1,158.61, suggesting a potential upside of 16.99%. Given Revolution Medicines' stronger consensus rating and higher probable upside, equities research analysts plainly believe Revolution Medicines is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.95
argenex	0 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.88

Summary

Revolution Medicines beats argenex on 8 of the 15 factors compared between the two stocks.

How does Revolution Medicines compare to Moderna?

Moderna (NASDAQ:MRNA) and Revolution Medicines (NASDAQ:RVMD) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

Revolution Medicines has lower revenue, but higher earnings than Moderna. Revolution Medicines is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	31.63	-$2.82B	-$7.99	N/A
Revolution Medicines	$11.58M	3,534.39	-$1.13B	-$8.82	N/A

Moderna presently has a consensus target price of $76.72, indicating a potential downside of 50.19%. Revolution Medicines has a consensus target price of $226.17, indicating a potential upside of 18.44%. Given Revolution Medicines' stronger consensus rating and higher probable upside, analysts clearly believe Revolution Medicines is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.08
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.95

Moderna has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market.

75.3% of Moderna shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 10.8% of Moderna shares are held by insiders. Comparatively, 7.6% of Revolution Medicines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Moderna had 9 more articles in the media than Revolution Medicines. MarketBeat recorded 33 mentions for Moderna and 24 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 0.57 beat Moderna's score of 0.40 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	11 Very Positive mention(s)	8 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Revolution Medicines	14 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Revolution Medicines has a net margin of 0.00% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-141.43%	-28.30%	-19.39%
Revolution Medicines	N/A	-88.20%	-57.85%

Summary

Revolution Medicines beats Moderna on 10 of the 17 factors compared between the two stocks.

How does Revolution Medicines compare to Natera?

Revolution Medicines (NASDAQ:RVMD) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

In the previous week, Revolution Medicines had 13 more articles in the media than Natera. MarketBeat recorded 24 mentions for Revolution Medicines and 11 mentions for Natera. Natera's average media sentiment score of 0.91 beat Revolution Medicines' score of 0.57 indicating that Natera is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	14 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Natera	7 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Natera has higher revenue and earnings than Revolution Medicines. Natera is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	3,534.39	-$1.13B	-$8.82	N/A
Natera	$2.71B	19.67	-$208.16M	-$1.36	N/A

Revolution Medicines has a net margin of 0.00% compared to Natera's net margin of -7.11%. Natera's return on equity of -11.38% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-88.20%	-57.85%
Natera	-7.11%	-11.38%	-7.87%

94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 99.9% of Natera shares are held by institutional investors. 7.6% of Revolution Medicines shares are held by insiders. Comparatively, 5.1% of Natera shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Revolution Medicines has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market. Comparatively, Natera has a beta of 1.54, meaning that its stock price is 54% more volatile than the broader market.

Revolution Medicines presently has a consensus price target of $226.17, suggesting a potential upside of 18.44%. Natera has a consensus price target of $330.83, suggesting a potential downside of 10.44%. Given Revolution Medicines' stronger consensus rating and higher probable upside, research analysts plainly believe Revolution Medicines is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.95
Natera	1 Sell rating(s)	4 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83

Summary

Revolution Medicines and Natera tied by winning 8 of the 16 factors compared between the two stocks.

Get Revolution Medicines News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RVMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RVMD vs. The Competition

Export

Metric	Revolution Medicines	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$42.21B	$3.91B	$7.25B	$13.13B
Dividend Yield	N/A	3.65%	2.57%	12.94%
P/E Ratio	-21.65	14.08	273.81	25.39
Price / Sales	3,534.39	1,407.75	692.78	109.00
Price / Cash	N/A	110.75	77.42	51.66
Price / Book	22.62	15.45	10.45	6.33
Net Income	-$1.13B	-$22.78M	$3.48B	$358.24M
7 Day Performance	-6.29%	-1.22%	0.88%	1.17%
1 Month Performance	-11.05%	-4.44%	-1.59%	-2.59%
1 Year Performance	338.56%	37.78%	18.08%	5.97%

Revolution Medicines Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RVMD Revolution Medicines	3.2653 of 5 stars	$190.95 -3.0%	$226.17 +18.4%	+322.3%	$42.21B	$11.58M	N/A	883	Trending News Insider Trade High Trading Volume
VRTX Vertex Pharmaceuticals	3.6482 of 5 stars	$546.12 flat	$569.52 +4.3%	+31.3%	$138.61B	$12.00B	31.79	6,400
REGN Regeneron Pharmaceuticals	3.7817 of 5 stars	$827.72 flat	$800.36 -3.3%	+31.1%	$85.22B	$14.34B	20.46	15,410
ARGX argenex	4.4836 of 5 stars	$1,033.15 flat	$1,158.61 +12.1%	+35.3%	$64.63B	$4.25B	39.68	1,863	News Coverage Analyst Downgrade Gap Up
MRNA Moderna	2.1613 of 5 stars	$145.55 flat	$76.72 -47.3%	+505.2%	$58.11B	$1.94B	N/A	4,700	Trending News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RVMD) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Revolution Medicines (RVMD) Competitors

RVMD vs. VRTX, REGN, ARGX, MRNA, and NTRA

How does Revolution Medicines compare to Vertex Pharmaceuticals?

Summary

How does Revolution Medicines compare to Regeneron Pharmaceuticals?

Summary

How does Revolution Medicines compare to argenex?

Summary

How does Revolution Medicines compare to Moderna?

Summary

How does Revolution Medicines compare to Natera?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RVMD vs. The Competition

Revolution Medicines Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Revolution Medicines (RVMD) Competitors

RVMD vs. VRTX, REGN, ARGX, MRNA, and NTRA

How does Revolution Medicines compare to Vertex Pharmaceuticals?

Do analysts rate RVMD or VRTX?

Does the media favor RVMD or VRTX?

Is RVMD or VRTX more profitable?

Which has more volatility & risk, RVMD or VRTX?

Do insiders & institutionals have more ownership in RVMD or VRTX?

Which has preferable earnings & valuation, RVMD or VRTX?

Summary

How does Revolution Medicines compare to Regeneron Pharmaceuticals?

Which has higher earnings & valuation, REGN or RVMD?

Do institutionals & insiders have more ownership in REGN or RVMD?

Does the media refer more to REGN or RVMD?

Do analysts prefer REGN or RVMD?

Which has more risk and volatility, REGN or RVMD?

Is REGN or RVMD more profitable?

Summary

How does Revolution Medicines compare to argenex?

Which has higher valuation & earnings, RVMD or ARGX?

Does the media favor RVMD or ARGX?

Is RVMD or ARGX more profitable?

Do institutionals and insiders have more ownership in RVMD or ARGX?

Which has more risk & volatility, RVMD or ARGX?

Do analysts prefer RVMD or ARGX?

Summary

How does Revolution Medicines compare to Moderna?

Which has better valuation & earnings, MRNA or RVMD?

Do analysts prefer MRNA or RVMD?

Which has more volatility & risk, MRNA or RVMD?

Do institutionals & insiders believe in MRNA or RVMD?

Does the media prefer MRNA or RVMD?

Is MRNA or RVMD more profitable?

Summary

How does Revolution Medicines compare to Natera?

Does the media favor RVMD or NTRA?

Which has stronger valuation and earnings, RVMD or NTRA?

Is RVMD or NTRA more profitable?

Do institutionals and insiders hold more shares of RVMD or NTRA?

Which has more volatility & risk, RVMD or NTRA?

Do analysts recommend RVMD or NTRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RVMD vs. The Competition

Revolution Medicines Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools